SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A1
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):November 7, 1997
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (Commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516-286-5800)
N/A
(Former name or former address, if changed since last report.)
<PAGE>
The contents of the FOrm 8K reportes for November 7, 1997, were erroneously
filed for that date istead of September 15, 1997, the earliest event reported. A
new 8K for September 15, 1997 has been filed containing the information
previously filed and other information which was erroneously on the November 7,
1997 filing. Reference is made to the Form 8K of September 15, 1997 for the
information concerning the Company's acquisition of Caribbean Medical Testing
Center, Inc. on September 15, 1997. The Form 8K for November 7, 1997, as amended
hereby may be disregarded.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Edward Fine
Edward Fine
President, Chief Executive Officer
(Signature)
Dated: December 2, 1997
